Cefoxitin, 3-carbamoyloxymethyl-7-a-methoxy-7-[2-(2-thienyl)acetamido]-3-cephem-4-carboxylic acid, a semisynthetic cephamycin antibiotic shown to have broad-spectrum activity in vitro, is active also in vivo against a wide variety of bacteria including penicillin-resistant staphylococci. It is, however, particularly effective against gram-negative organisms including strains of indole-positive Proteus against which cephalothin and cephaloridine are ineffective. When cefoxitin is given subcutaneously, concentrations in mouse blood, urine, and other tissues are higher than those seen for cephalothin. Higher concentrations in the blood and greater therapeutic efficacy are achieved with cefoxitin when it is given with probenecid. For this reason it is believed that cefoxitin is excreted mainly by way of the renal tubules. The data indicate that cefoxitin has potential as a therapeutically useful antibiotic.
Two naturally occurring 7-methoxylated cephalosporins were described by Nagarajan et al. (10) . One of these was among the three described independently by Stapley et al. (13) who designated this class of compounds cephamycins. To produce agents of greater activity and a broader spectrum, these naturally occurring antibiotics have been modified chemically (1, 5) . In one analogue of cephamycin C, the aminoadipoyl sidechain at C-7 is replaced with a thienylacetyl group. This antibiotic, cefoxitin, 3 -carbamoyloxymethyl -7 -a -methoxy -7 -[2 -(2-thienyl)acetamido] -3 -cephem -carboxylic acid was shown to have broad antibacterial activity in vitro (14) . The present paper describes some of the pharmacological properties of cefoxitin and its therapeutic efficacy in mice against a number of systemic infections.
MATERIALS AND METHODS
Crystalline cefoxitin sodium salt and a laboratory sample of cephamycin C sodium, of approximately 70% purity, were used as water solutions in these tests. Commercial samples of cephalothin, (Keflin, Lilly), cephaloridine (Loridine, Lilly), ampicillin (Penbritin-S, Ayerst), and methicillin (Staphcillin, Bristol) were solubilized aseptically with sterile water.
Efficacy studies. As a standard procedure, Charles River CD1 female mice, weighing 18 to 20 grams, were infected intraperitoneally with 3 to 100 times the number of organisms that should kill 50% of the infected, nontreated animals (LD,0). Five mice were used at each of the fourfold drug concentrations tested. Therapy was given by the indicated route at the time of infection and again 6 h later. The test was terminated 7 days after infection, and the survival records of that day were used to calculate the number of organisms in the challenge LD,0 and also the ED50, i.e., the amount of antibiotic that should protect 50% of the infected, treated animals (7).
For most of the test organisms the challenge preparation consisted of appropriate dilutions in brain heart infusion of broth cultures of the test strain. Some organisms, however, were used as suspensions in 5% hog gastric mucin. These were strains of Enterobacter, Proteus vulgaris, and Proteus morganii 3376.
Pharmacological studies: antibiotic concentration in blood and other tissues. Mice, chosen to weigh 20 g, were given 400 gg (20 mg/kg) of the test substance by the indicated route. Each animal also was given 0.5 ml of water by gavage to stimulate urine flow. Groups of five or six animals were used for each time interval tested, and each group was placed in a metabolism cage so that urine could be collected. At the indicated interval, the urine sample was measured and frozen and the mice were bled from the heart. The pooled blood was allowed to clot and the collected serum also was frozen. Other tissues, collected from these same mice, were pooled and weighed. They were prepared for assay by grinding in 0.075 M phosphate buffer (pH 6) using a motor-driven Teflon pestle in a glass grinding tube. Such suspensions were diluted I with the buffer to a final concentration of RESULTS AND DISCUSSION Efficacy studies. The therapeutic effectiveness of the tested antibiotics against four grampositive and 20 gram-negative systemic infections in mice is listed in Table 1 . Generally, the in vivo activities confirm the in vitro data reported by Wallick and Hendlin (14) . The replacement of the aminoadipoyl side chain of cephamycin C with the thienylacetyl group produced a compound with markedly enhanced gram-positive activity and with increased activity against at least two of the tested gram-negative organisms, Enterobacter cloacae 2646 and Escherichia coli Moran.
Against gram-positive organisms, the cephalosporins are more active than are the cephamycins. However, against the cephalosporinsensitive gram-negative bacteria, cefoxitin generally was more active than cephalothin. In addition, cefoxitin is active against strains of E. coli, indole-producing Proteus, and Serratia that are refractory to treatment with the cephalosporins. It is interesting to note the activities of the antibiotics against two strains of E. cloacae that were obtained from M. Goldner (4) . Both the cephalosporins and the cephamycins protected mice against strain 2647, but only cefoxitin was effective at a tested concentration against the lactamase producing 2646. Enzymatic studies (Onishi et al. [11] ) indicate that cefoxitin is degraded by the lactamase of E. cloacae at a much slower rate than are the cephalosporins. It may be, as Onishi suggests, that the susceptibility of strain 2646 to cefoxitin is a reflection of the refractility of the antibiotic to enzymatic degradation. Table 2 shows protection data from tests using a penicillin-sensitive and each of two penicillin-resistant, methicillin-sensitive strains of staphylococci as infecting agents. Methicillin and ampicillin were included as positive and negative control antibiotics. Cefoxitin, although not so active as the cephalosporins against the penicillin-sensitive strain, showed no loss of this activity when tested against penicillin-resistant organisms. For cephaloridine, 100 to 200 times more antibiotic was required to control the infections produced by the penicillin-resistant strains than was needed for the penicillin-sensitive strain. For cephalothin, 16 to 37 times, and, even for methicillin, 3 times more antibiotic was required. Ampicillin, sensitive to degradation by penicillinase, showed evidence of activity against one of the penicillin-resistant strains only at 700 or more times the amount needed to protect against the sensitive strain.
The equivalence of the cephalosporins and cefoxitin for penicillin-resistant staphylococci probably reflects the stability of cefoxitin.to the action of f8-lactamase, since cephalosporins highly effective against 6-lactamase-producing staphylococci are said (12) to be, without exception, highly resistant to inactivation by their enzymes.
Pharmacological studies: concentrations in the blood and other tissues. Concentrations of antibiotic were determined in the serum, urine, and other tissues of mice that had received subcutaneously a 20 mg dose of cephalothin, cephaloridine, or cefoxitin per kg. Because the biological assay developed for this latter antibiotic is less sensitive than those used for cephalothin and cephaloridine, the distribution of cefoxitin was measured by determining the radioactivity in tissues of mice given cefoxitin labeled with 14C in the thienylacetamido side chain. Both radio-and bioassays were carried out to determine the cefoxitin content of serum and urine specimens. The data agreed well within experimental variation of the assays and demonstrated the validity of using the radioassay rather than the less sensitive bioassay to determine concentrations of cefoxitin in the solid tissues.
The data in Table 3 show that cefoxitin is found in sera and detected in urine samples in amounts greater than those of cephalothin and less than those of cephaloridine. The similarity of data obtained from bio-and radioactivity assays of urine samples suggest that cefoxitin is excreted as the intact molecule and not as a metabolite.
Concentrations of the three antibiotics in solid tissues at various times after subcutaneous injection are shown in Table 4 . Again, cefoxitin is demonstrated in concentrations greater than cephalothin and approaching those of cephaloridine. It is known that cephalothin is excreted both as the intact antibiotic and in the deacetylated form (8) . All the appropriate samples of these experiments were assayed against a cephalothin standard with an assay organism against which desacetylcephalothin was shown to be only one-fourth as active as is cephalothin. Our values therefore represent all the intact cephalothin and perhaps 25% of the desacetylcephalothin that may be present.
Effect of probenecid on the concentrations of antibiotics in the blood and its detection in urine. It is known that the use of probenecid enhances the concentration of cephalothin in the serum and delays the excretion of the antibiotic (8) . Since probenecid acts by repressing tubular but not glomerular excretion, cephalothin is said to be excreted both by glomerular filtration and by tubular secretion. On the other hand, it is reported that cephaloridine is excreted mainly by glomerular filtration since probenecid treatment has only a minimal effect on the concentration of this antibiotic in the serum and urine (6) . We have reported (9) that since neither cephamycin C nor cephalosporin C concentrations in the blood were enhanced by the use of probenecid, these two antibiotics also are excreted mainly by glomerular filtration. Experiments were carried out to determine the effect of probenecid on the concentrations in the blood and the urinary excretion by the mouse of cefoxitin, cephalothin, and cephaloridine.
Data obtained from such experiments are shown in Table 5 . It can be seen that there indeed is no probenecid effect on serum values of cephaloridine, but there is such an effect both for cephalothin and for cefoxitin. Both the peak concentrations and the duration of detectable antibiotic in the sera are enhanced when probenecid is given at the same time as these latter two antibiotics. The amounts of these agents detected in the 0-to 4-h urine samples do not seem to be altered by the probenecid dose, although there may be a depression in the early excretion of cefoxitin and cephalothin.
Experiments then were performed to determine whether the enhanced concentrations of antibiotic in the sera were of therapeutic value. That this is the case is shown by the data in Table 6 . The therapeutic effectiveness of cefoxitin and of cephalothin against both gram-negative and gram-positive infections was enhanced two-to threefold in probenecid-treated mice, where the activity of cephaloridine was not influenced by probenecid. Earlier tests using only Salmonella schottmuelleri as the infecting agent showed, as expected, no enhancement by probenecid of the therapeutic activity of cephamycin C. From these present tests we suggest that cefoxitin, as cephalothin, is excreted both by the glomerular and tubular mechanisms, that the tubular excretion can be influenced by probenecid resulting in elevated and prolonged concentrations of antibiotic in the blood, and that such enhanced concentrations of antibiotic are therapeutically useful. It is of interest that changing the 7,C side chain of the naturally occurring cephamycin C from aminoadipoyl to thienylacetyl produced a compound with an extended antibacterial spectrum, with greater activity against cephalosporin-resistant organisms, and excreted in a manner different from that of the parent antibiotic. Since, in these studies as much as two doses of 8 mg each (400 mg/kg) were given subcutaneously 6 h apart without any evidence of toxicity, cefoxitin, like cephamycin C, is a well-tolerated antibiotic.
The good antibacterial activity of this antibiotic, especially against gram-negative organisms and those resistant to inhibition by cephalosporins, indicates that cefoxitin has potential as a therapeutic agent in man.
